Quantcast

Latest Phenols Stories

2014-07-30 08:33:40

LONDON, July 30, 2014 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has received a funding commitment from a prominent international research and development foundation. The foundation has a focus on promoting innovative research-based initiatives, including those addressing health issues. Lightlake has been developing a nasal...

2014-07-30 08:33:01

Primary efficacy endpoints met in all nine new trials of investigational PCSK9 inhibitor TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo...

2014-07-29 08:34:16

WAYNE, Pa., July 29, 2014 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced that its second quarter financial results will be released on Tuesday, August 12, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 am Eastern Time to review the Company's financial and operating results and provide a general business update. The live webcast and a replay may be accessed by visiting Egalet's website. Please...

2014-07-29 08:31:39

MELBOURNE, Australia, July 29, 2014 /PRNewswire/ -- -- Next phase of the TPM®/Oxymorphone clinical development program has commenced -- TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4 2014 -- TPM®/Oxymorphone Phase 2 trial to be conducted in the United States in 1H 2015 Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today provided updates on its opioid transdermal patch programs after its...

2014-07-23 23:03:28

In its latest blog post, Best Drug Rehabilitation, which offers treatment programs and believes that having family close by during a stay in rehab can make a big difference in whether or not the process is successful, is focusing on a topic that is quickly becoming among the most important of all drug and addiction-related dialogues: opiate abuse facts. (PRWEB) July 23, 2014 In its latest blog post, Best Drug Rehabilitation, which offers treatment programs and believes that having family...

2014-07-22 08:31:15

RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of...

2014-07-16 08:28:03

FDA also approves the use of two Butrans patches for dose adjustments in appropriate chronic pain patients STAMFORD, Conn., July 16, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) approved a new 7.5 mcg/hour dosage strength of Butrans(®) (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. The Butrans Transdermal System is also...

2014-07-15 23:14:30

Avail is conducting a Phase 2, randomized, placebo-controlled clinical research study to evaluate the efficacy, safety and pharmacokinetics of an experimental spray treatment for qualified participants with mild to moderate osteoarthritis (OA) of the knee. DeLand, FL (PRWEB) July 15, 2014 *To see if you qualify for this Osteoarthritis Clinical Trial in DeLand, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost...

2014-07-15 16:27:44

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023https://www.reportbuyer.com/product/2166742/Pristiq-Major-Depressive-Disorder---Forecast-and-Market-Analysis-to-2023.htmlPristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023SummaryMajor depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

2014-07-10 08:27:14

First and only FDA approved naloxone product specifically indicated for emergency therapy in settings where opioids may be present. RICHMOND, Va., July 10, 2014 /PRNewswire/ -- Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO is not a...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related